- Home
- PMM vs ALDX Comparison
PMM vs ALDX Comparison
Compare PMM & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMM | ALDX |
|---|---|---|
| Founded | 1989 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.4M | 293.0M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | PMM | ALDX |
|---|---|---|
| Price | $6.22 | $5.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 118.3K | ★ 1.5M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $36.25 |
| P/E Ratio | $26.52 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.00 | $1.14 |
| 52 Week High | $6.42 | $7.20 |
Technical Indicators
Market Signals| Indicator | PMM | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 55.00 | 51.50 |
| Support Level | $6.15 | $5.04 |
| Resistance Level | $6.21 | $5.75 |
| Average True Range (ATR) | 0.08 | 0.47 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 53.85 | 67.04 |
Price Performance
Historical ComparisonAbout PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.